Carmen Baquero

发表

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Jian Du, R. Beckmann, S. Buchanan, 2017, Oncotarget.

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Shobha N. Bhattachar, R. Campbell, Y. Qian, 2019, Molecular Cancer Therapeutics.

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation

Jian Du, C. Mur, Yanzhu Yang, 2022, Oncotarget.

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

J. Benach, H. Broughton, C. Rauch, 2022, npj Breast Cancer.

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.

C. Caldwell, P. Iversen, Jian Du, 2017, Cancer cell.

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Jian Du, R. Beckmann, S. Buchanan, 2017, Oncotarget.

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Huimin Bian, Shaoyou Chu, Anna Pustilnik, 2018, Cancer discovery.

Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene.

Phillip W Iversen, Thompson N. Doman, Huimin Bian, 2019 .

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

J. Benach, H. Broughton, C. Rauch, 2022, npj Breast Cancer.

Aurora A ligand complex

T. Doman, R. Campbell, Jian Du, 2019 .